CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Learn what to say when asking for financial assistance. Clear communication can help you express your needs effectively.
21,968 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Apple rolled out a beta Siri upgrade with limited regional access, keeping EU and China on the sidelines. Investors a...
A leading hedge fund investor says the current AI rally is fundamentally different from the late-1990s bubble, citing...
Private markets are stuck in a funding logjam, with longer waiting times and shrinking payouts, signaling that the ci...
A top AI firm treads a thin line: warning about AI power while pushing new, powerful tools to market. This raises que...
The 2026 COLA boosted Social Security checks, yet a fixed Medicare premium cut into those gains, changing how retiree...
Rivian is rolling out its smaller R2 SUV, and deliveries have begun. As investors watch the headlines, the big questi...
As AI workloads surge, investors wonder if Applied Digital could be an undervalued play. This guide breaks down how t...
A reported breakthrough on Iran negotiations sparked a risk-on market rally and shifted bets on the Federal Reserve's...
A veteran investor argues Talen Energy is undervalued versus its replacement cost, with potential for a doubling or m...
A deep dive into mib: jean eric salata, chair of EQT, exploring how cross-cultural experience and AI-driven infrastru...
A globe-trotting investor proves you don’t need hundreds of doors to fund your freedom. With three well-chosen rental...